Guardian Raised Its 2026 Target to $1.45B-But the EBITDA Math Makes IRA Fear Hard to Ignore

The guidance raise puts revenue next to EBITDA

Guardian is asking the market to back updated 2026 revenue of $1.43 billion-$1.45 billion and adjusted EBITDA of $129 million-$131 million. The headline looks bullish, but the real question is whether that profit target still holds up after IRA-related pricing reductions.

Why the EBITDA target matters more than the revenue headline

This was not a hollow setup. In 2025, revenue rose 18%, adjusted EBITDA rose 27%, year-end cash was $65.6 million, and residents served were approximately 205,000. That suggests a business that was still building scale and profitability before the latest pricing pressure showed up in reported revenue growth.

Then came the second quarter. Revenue grew just 2% year-over-year, but residents served still rose 8%, and adjusted EBITDA reached $29.7 million. Management said IRA-related pricing reductions affected reported revenue growth. That is the core tension: bulls see demand and profit still moving in the right direction, while bears see a thinner bridge between resident growth and revenue realization.

Resident growth still suggests demand is intact

Guardian does not need a perfect revenue print to show the business is relevant; it needs evidence that facilities continue to rely on its platform.

The resident count is still moving higher

End-2025 resident count was approximately 205,000. By end-Q2 it was approximately 210,000, and Q2 resident growth was up 8% year-over-year. In long-term care pharmacy, that kind of growth usually points to a vendor that is still proving useful to facilities day to day.

EBITDA held up even with weaker reported revenue

The second-quarter margin story is more nuanced, but still constructive. Adjusted EBITDA rose to $29.7 million from $25.0 million a year earlier even though revenue grew only 2%. Management also said Absent the price reductions from the IRA, revenues would have been up low double digits compared to the second quarter of 2025. That does not settle the debate on pricing power, but it does suggest the profit pool was not immediately damaged by the headwind.

The debate now is durability, not whether the business is slipping

Guardian's latest quarter gives both sides a credible argument. The company still seems operationally active, but the market has to decide how much IRA pricing pressure can be absorbed without breaking the 2026 profit outlook.

What supports the bullish read

• Resident growth remained healthy at approximately 210,000 and up 8% year-over-year.
• Adjusted EBITDA remained above the prior-year level in Q2.
• Cash and cash equivalents totaled $89.8 million at quarter-end, up sharply from $4.7 million at the end of 2024, giving the company more room to navigate pricing pressure.

What keeps the bear case alive

• Reported revenue grew only 2% year-over-year.
• Management said IRA-related pricing reductions affected reported revenue growth, so the negative impact is real, even if its durability is still unclear.
• A stronger EBITDA number in one quarter does not automatically prove durable pricing power over multiple quarters.

What investors need to see next

The next few quarters should clarify whether Guardian is managing through a temporary pricing reset or facing a more persistent margin squeeze.

Watch for: - another quarter of EBITDA above the prior-year level, not just a single-quarter holdup - resident growth that continues after approximately 210,000 - cash near $89.8 million at quarter-end, reflecting continued financial flexibility - management showing whether the gap between reported revenue growth and underlying demand is narrowing or staying wide